Systemic health inequities disproportionately impact underserved racial and ethnic populations, leading to higher morbidity, mortality, and reduced quality of life. Socioeconomic disadvantages, racial bias, and barriers to care contribute to these disparities, yet they often go unnoticed by health care …
The rapidly evolving multiple myeloma (MM) treatment landscape has created unprecedented opportunities, while introducing new complexities for clinicians caring for patients with relapsed/refractory (R/R) disease. In just a few years, bispecific antibodies (BsAbs) have emerged as highly effective treatment options, …
Endometriosis is a chronic inflammatory condition that remains underrecognized and undertreated, leaving many individuals of reproductive age with daily pain and disruption. Patients often face preference‑sensitive decisions about pain management, contraception, and fertility without clear guidance, frequently after years‑long diagnostic …
Despite national recommendations, PrEP remains underutilized in many clinical settings because clinicians often lack confidence, time, and practical workflows to consistently identify candidates and act on eligibility findings. Routine care frequently omits a structured sexual health history and assessment, leading …
Despite advances in the prevention and management of atherosclerotic cardiovascular disease (ASCVD), gaps remain in real-world risk assessment and lipid-lowering treatment, particularly among intermediate- and high-risk patients. Inconsistent use of risk assessment tools, variable evaluation of risk-enhancing factors, and suboptimal …
Alzheimer’s disease (AD) is an escalating public health challenge, with rising prevalence and profound burdens on patients, caregivers, and healthcare systems. Recent approvals of amyloid-targeting therapies (ATTs) represent a major advancement in disease-modifying treatment for early symptomatic AD. However, translating …
Alzheimer’s disease (AD) continues to impose a growing public health burden as prevalence rises alongside an aging population. Despite advancements in diagnostic tools and the emergence of Alzheimer’s-targeted therapies (ATTs), many healthcare professionals (HCPs) face challenges in integrating new evidence …
Alzheimer’s disease (AD) remains a leading cause of cognitive decline and functional impairment in older adults, with early diagnosis and intervention offering the greatest opportunity to preserve quality of life. The emergence of novel disease-modifying, amyloid-targeting therapies (ATTs) has created …
As HER2-low and ultralow classifications reshape metastatic breast cancer (mBC) treatment pathways, many practices still face real-world barriers to accurate testing and timely reporting. Intra-laboratory variability, limited uptake of emerging assays, and fragmented communication across care teams can all lead …